McDermott Advises Tissium on its Series D Fundraising

McDermott Will & Emery advised Tissium, a privately held medtech company specializing in the development of biomorphic programmable polymers for tissue reconstruction, in a Series D fundraising.

Tissium is raising EUR 50 million to pursue its development plan, finance the commercialization of its first products for peripheral nerve repair and hernia repair in the USA, and expand its product portfolio and technology platform.

New investors, including the Fonds Stratégique des Transitions (managed by ISALT) and Mérieux Développement, joined the round alongside existing investors Cathay Health, Crédit Mutuel Innovation and Sofinnova Partners.

The McDermott team advising Tissium comprised:

• Bertrand Delafaye, partner, Marie Mouly and Pénélope Renard, associates.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.